NCT04207957View on ClinicalTrials.gov

A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

September 15, 2020

Study Completion Date

September 15, 2020

Conditions

Healthy

Interventions

DRUG

Olorofim

150 mg

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit, Leeds

Sponsors

Lead Sponsor

F2G Biotech GmbH

Collaborators (1)

All Listed Sponsors

collaborator

Covance

INDUSTRY

lead

F2G Biotech GmbH

INDUSTRY